Gateway Pharmaceutical is a specialty drug-delivery company focusing on reformulation of traditional antibiotics for target delivery of drug to bacteria location.
Our Team has an average of more than
15 years of pharmaceutical industrial experience in formulation and process development, analytical testing, scale-up manufacturing, pharmacokinetic and clinical studies, and regulatory submission.
Innovating site-specific delivery of antibiotics to combat antibiotic resistance threats to the United States and the World.
BioSTL Award in 2018 Venture Showcase
September, 2020 – We received the NIH NIAID Pre-Clinical Service Award on GMP manufacturing of Metronidazole Delayed-Release Capsules for treating Clostridium difficile infection.
March, 2020 – Our key colon-delivery patent 10,588,864 received approval from the US PTO.
August, 2018 – We received the NIH SBIR Phase I grant on Metronidazole Colon-Delivery for treating Clostridium difficile Infection.
November, 2018 – Gateway won the BioSTL Award on the 10th Startup Connection Venture Showcase in St. Louis.